Where a 7% dividend yield hides a multitude of issues
Updates covered here include a trading update from an unusual provider of alternative finance solutions, which comes with the appeal of big dividend payments. We question the merits of its unusual business model. Read on for this and other news from AIM.
IXICO: another nice contract win for one of our Bonkers Bargains
IXICO (AIM: IXI), the precision analytics company delivering intelligent insights in neuroscience and one of our Bonkers Bargain selections, announced that it has been selected by a leading European biopharmaceutical company to provide MRI and DAT-SPECT imaging services for a Phase 2 clinical trial in Parkinson's disease.
You can read our Bonkers Bargain overage on this business here.
Sign up and read the full article
Register to continue reading our content.
Already a member? Login
Previous article Next article